Media Centre
Look who's talking about us!
Traditionally gastric balloon procedures have involved a 3-4 hour hospital stay for an endoscopic insertion followed by a second visit when it’s ready for removal. Not any more! The Allurion swallowable gastric balloon is a new innovation in balloon technology requiring no endoscopy, no sedation and no removal procedure.
Natick healthcare firm Allurion Technologies has rebranded its products to integrate its weight-loss balloon that doesn't require surgery and passes naturally through the body with a weight-loss program with a digital app.
Allurion Technologies has transformed its Allurion Weight Loss Program and new worldwide brand for the company and its programme. Allurion began commercial sales of its flagship Elipse Gastric Balloon in 2016.
Net of the various considerations, among the 10 main reasons why Italians coming out of the pandemic feel stressed, there is the increase in the waistline that creates more anxiety – in some people – than the economic crisis or poor social life.
A new Weight loss Device that promises surgical results without the operation has been approved for use in Australia.
The Elipse gastric balloon is a capsule with an attached tube that is swallowed by a patient who wants to lose unwanted pounds.
Our weight and eating habits have been brought more into focus over the last year. Not only have we continually heard the news about links between obesity and poorer outcomes with COVID-19, but the lockdown restrictions have significantly impacted upon our daily routines, work, social life and exercise habits.
Shantanu Gaur co-founded Allurion Technologies with Samuel Levy in 2009. Shantanu completed his A.B. in Biology from Harvard College, where he graduated summa cum laude with election to Phi Beta Kappa. Shantanu received his M.D. from Harvard Medical School.
With 20 years' experience in the medical aesthetics, weight-loss, and skincare industries, Benoit's high level of energy and ability to lead global and cross functional teams is a key element to Allurion's success. He has held executive positions at high-growth start-ups including Filorga and Zeltiq and two of the world’s most renowned medical aesthetic players: Galderma and Allergan.
Dr. Chuttani is internationally recognized as a leader in digestive disease care and has pioneered numerous innovative technologies. Prior to joining Allurion, Dr. Chuttani was the Director of Endoscopy and Chief of Interventional Gastroenterology at Beth Israel Deaconess Medical Center (BIDMC).
To contact our PR team with any media enquiries or opportunities, please get in touch with:
Natalie King at press@allurion.com